Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07079670 · ClinicalTrials.gov registry record · Phase 3

Safety and Immunogenicity of NVX-CoV2705

A Phase 3 study of COVID-19 and SARS CoV 2 Infection, sponsored by Sanofi.

Active
Registry status
Phase 3
Development phase
676
Enrollment target
10
Study locations

NCT07079670 is a Phase 3 study of COVID-19 and SARS CoV 2 Infection that is active but no longer recruiting, run by Sanofi. The registered enrollment target is 676 participants, below the 55,211-participant average among 203 other COVID-19 trials with a reported enrollment target (99% lower). The trial reports 10 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07079670, a Phase 3 study of COVID-19 and SARS CoV 2 Infection, is active but no longer recruiting, sponsored by Sanofi.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
676 participants
Enrollment target
10
Study locations

Study Summary

This study is a Phase 3 trial designed to check the safety and immune response to a new Omicron JN.1 COVID-19 vaccine. Study researchers will give a single dose of this vaccine, called NVX-CoV2705, to approximately 120 participants. This includes adults aged 65 and older, and individuals aged 12 to 64 who have existing health conditions that put them at high risk for severe COVID-19. All participants must have received a previous COVID-19 vaccine at least 90 days before joining this study. Study researchers will be closely monitoring participants for their immune response for 28 days and collecting safety data for 180 days after vaccination.

Conditions Studied

COVID-19 SARS CoV 2 Infection

Interventions

  • BIOLOGICAL NVX-CoV2705

Study Locations (10)

Texas

  • Investigational Site Number US047 - Austin
  • Investigational Site Number US073 - Tomball

Arizona

  • Investigational Site Number US404 - Phoenix

Illinois

  • Investigational Site Number US395 - Melrose Park

Kansas

  • Investigational Site Number US406 - Lenexa

Louisiana

  • Investigational Site Number US294 - Lafayette

Michigan

  • Investigational Site Number US407 - Southfield

Nebraska

  • Investigational Site Number US326 - Omaha

Ohio

  • Investigational Site Number US381 - Cincinnati

Trial Details

FieldValue
Enrollment Target 676 participants
Start Date 2025-10-09
Est. Completion 2026-06-16
Phase Phase 3

Sponsor

Sanofi

713 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07079670

The ClinicalTrials.gov registry entry for NCT07079670 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 676 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,211-participant average among 203 other COVID-19 trials with a reported enrollment target (99% lower). The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with COVID-19 appearing as the primary indexed condition, and to 1 intervention - of which NVX-CoV2705 is the first listed.

NCT07079670 reports 10 study locations spanning 9 distinct geographic areas - top geographies include Texas, Arizona, Illinois.

Frequently Asked Questions

What is clinical trial NCT07079670 about?

NCT07079670 is a clinical study titled "Safety and Immunogenicity of NVX-CoV2705". This study is a Phase 3 trial designed to check the safety and immune response to a new Omicron JN.1 COVID-19 vaccine. Study researchers will give a single dose of this vaccine, called NVX-CoV2705, to approximately 120 participants. This includes adults aged 65 and older, and individuals aged 12 to ...

What is the current status of trial NCT07079670?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 676 participants. The study started on 2025-10-09. Estimated completion is 2026-06-16.

What conditions does trial NCT07079670 study?

This clinical trial studies the following conditions: COVID-19, SARS CoV 2 Infection.

What interventions are being tested in trial NCT07079670?

The interventions under investigation include: NVX-CoV2705 (BIOLOGICAL).

Who is sponsoring clinical trial NCT07079670?

This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07079670 being conducted?

This trial has 10 study locations across Arizona, Illinois, Kansas, Louisiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for COVID-19

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

COVID-19

All registered trials for this condition

SARS CoV 2 Infection

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.